Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive following the Therapeutic Goods Administration (TGA)’s decision to down-schedule MDMA and psilocybin to Schedule 8 'Controlled Medicines' from July 2023. Winlo says the clinical-stage biotech, backed by Australian billionaire Andrew Forrest, is well-positioned to accelerate patient access to MDMA-assisted therapies. Rescheduling MDMA opens a pathway to registration and reimbursement for MDMA and its analogues.
Emyria ramps up MDMA programs following ‘incredible’ TGA decision
